A federal judge has ruled that CVS' purchase of Aetna was legal under antitrust law; the Trump administration announced $1.8 billion in grants to help states and communities combat the opioid epidemic; Johns Hopkins Medicine has launched the first psychedelic research center in the United States.
A federal judge has approved CVS’ purchase of Aetna, agreeing with a Justice Department decision that the merger is legal under antitrust law, Reuters has reported. A government plan announced in October said it would allow the merger on the condition that the health insurer sell its Medicare prescription drug plan business to WellCare Health Plans. Both deals have already closed, and since then, Centene has agreed to acquire WellCare for $15.27 billion. CVS said the judge’s decision reinforced that CVS and Aetna have already merged.
The Trump administration on Wednesday announced that it is awarding $1.8 billion in grants to help combat the opioid epidemic. Approximately $980 million will go to states and some territories to focus on prevention and treatment, including through expanding rural telemedicine, expanding access to overdose reversal drug naloxone, and prevention programs. According to The Wall Street Journal, another $900 million will go to CDC over 3 years in order to help states and communities track overdose data and implement treatment strategies.
Johns Hopkins Medicine has launched the Center for Psychedelic and Consciousness Research, the first of its kind in the country. The center will study substances like LSD and psilocybin for a variety of mental health conditions, including anorexia, addiction, and depression, reported The New York Times. The center was created with $17 million in funding from private donors and a foundation. Some scientists have been exploring the potential of psychedelics and other recreational drugs for psychiatric problems since the early 2000s.
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
April 16th 2025A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Complete Responses Seen With Emerging Therapies for Chronic Spontaneous Urticaria
April 16th 2025There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and barzolvolimab showing complete response in patients, particularly among those who are difficult to treat.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More